This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to determine the maximal tolerated dose for the combination of bortezomib and suberoylanilide hydroxamic acid (SAHA). In addition, researchers will also evaluate the blood levels, anti-tumor activity, and side effects of this combination. Correlative research will also be conducted on plasma, tumor tissue, and mouth swabs collected during the
Showing the most recent 10 out of 459 publications